Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 4;22(1):11.
doi: 10.1186/s40360-021-00476-z.

New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins

Jah Yeon Choi  1 , Cheol Ung Choi  2 , Byoung Geol Choi  1 , Yoonjee Park  1 , Dong Oh Kang  1 , Won Young Jang  3 , Woohyeun Kim  1 , Jin Oh Na  1 , Jin Won Kim  1 , Eung Ju Kim  1 , Seung-Woon Rha  1 , Chang Gyu Park  1 , Hong Seog Seo  1 , Myung Ho Jeong  4 , Sung-Chull Chae  5 , In-Whan Seong  6 , Chang-Hwan Yoon  7 , Kwang Soo Cha  8 , Seok Kyu Oh  9 ; KAMIR-NIH Investigators
Collaborators, Affiliations

New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins

Jah Yeon Choi et al. BMC Pharmacol Toxicol. .

Abstract

Background: High-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. However, there have been consistent concerns regarding its association with diabetes mellitus. We investigated the effect of high-intensity atorvastatin and rosuvastatin on new-onset diabetes mellitus (NODM) and cardiovascular outcomes over a 3-year follow-up period.

Methods: Data from the Korea Acute Myocardial Infarction Registry were collected from November 2011 to October 2015, and 13,104 patients with AMI were enrolled from major cardiovascular centers. Among them, 2221 patients without diabetes who had been administered with high-intensity atorvastatin (40-80 mg) and rosuvastatin (20 mg) were investigated. The atorvastatin and rosuvastatin groups were evaluated for the incidence of NODM and major adverse cardiac events (MACE) including death, myocardial infarction, and revascularization cases in the following 3 years.

Results: Baseline characteristics were comparable between the two groups. Event-free survival rate of NODM was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value = 0.550). The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. 89.6%, respectively; Log rank P-value = 0.662). Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE.

Conclusions: Administering high-intensity atorvastatin and rosuvastatin in patients with AMI produced comparable effects on NODM and clinical outcomes, suggesting their clinical equivalence in secondary prevention.

Keywords: Acute myocardial infarction; Atorvastatin; Cardiovascular outcome; New-onset diabetes mellitus; Rosuvastatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Patient flow chart. AMI: Acute myocardial infarction, DM: diabetes mellitus, KAMIR: Korea Acute Myocardial Infarction Registry, MACE: major adverse cardiac events, PCI: percutaneous coronary intervention, POBA: plain old balloon angioplasty
Fig. 2
Fig. 2
Kaplan–Meier curves for event-free survival rate of new-onset diabetes mellitus (a) and major adverse cardiac events (b) according to statin type
See this image and copyright information in PMC

References

    1. Betteridge DJ, Carmena R. The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99–110. doi: 10.1038/nrendo.2015.194. - DOI - PubMed
    1. Lee J, Noh Y, Shin S, Lim HS, Park RW, Bae SK, Oh E, Kim GJ, Kim JH, Lee S. Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Ther Clin Risk Manag. 2016;12:1533–1543. doi: 10.2147/TCRM.S117150. - DOI - PMC - PubMed
    1. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, Seshasai SRK, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742. doi: 10.1016/S0140-6736(09)61965-6. - DOI - PubMed
    1. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564. doi: 10.1001/jama.2011.860. - DOI - PubMed
    1. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [JAPAN assessment of pitavastatin and atorvastatin in acute coronary syndrome] study) J Am Coll Cardiol. 2009;54(4):293–302. doi: 10.1016/j.jacc.2009.04.033. - DOI - PubMed

Publication types

Substances